Skip to main content

Table 2 Comparison of the baseline characteristics of ICS withdrawal group and ICS continued group

From: Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts

  Withdrawal (n = 77) Continued (n = 378) p-value
Age 67.9 ± 8.3 68.4 ± 7.8 0.67
Male 74(96.1) 345(91.5) 0.24
Smoking status    0.72
 Current smoker 27(35.1) 116(31.1)  
 Ex-smoker 46(59.7) 231(61.9)  
 Non-smoker 4(5.2) 26(7.0)  
 Pack-years 43.7 ± 25.6 43.4 ± 24.9 0.93
BMI 23.1 ± 3.5 23.0 ± 3.3 0.47
SGRQ 34.0 ± 19.4 33.0 ± 18.6 0.65
CAT 15.9 ± 0.9 16.3 ± 0.4 0.90
mMRC 1.5 ± 0.9 1.6 ± 0.8 0.71
Post-BD FEV1, L 1.45 ± 0.44 1.48 ± 0.54 0.63
Post-BD FEV1, % predicted 54.0 ± 15.3 55.9 ± 19.9 0.44
Post-BD FEV1/FVC ratio 47.6 ± 11.0 47.9 ± 12.5 0.83
Bronchodilator Response    0.41
 None 67(87) 307(81.2)  
 BDR > 12% and 200 ml (FEV1) 7(9.1) 56(14.8)  
 BDR > 15% and 400 ml (FEV1) (Spanish ACO) 3(3.9) 15 (4.0)  
DLco, % predicteda 70.2 ± 24.0 74.1 ± 23.8 0.24
Asthma 43 (56.6) 152 (41) 0.01
Exacerbation frequency, events/person-year 0.79 ± 2.35 0.53 ± 1.39 < 0.001
Serum eosinophils cells/μlb 177(84–325) 190(113–327) 0.23
 Eosinophils > 300 cells/μl n (%) 14(25.5) 79(28.9) 0.6
GOLD group    0.39
 A 32(42.7) 171(46.1)  
 B 28(37.3) 134(36.1)  
 C 8(10.7) 21(5.7)  
 D 7(9.3) 45(12.1)  
  1. Continuous data are presented as mean ± SD or median (interquartile range). Categorical variables as No. (%) unless otherwise indicated. See Table 1 legend for expansion of abbreviations. an = 382, bn = 328